The findings suggest that YAP activation due to NF2 loss mediates resistance to Bcl-xL inhibitors in Rasa1 deficient cells and highlights the potential of combining YAP and Bcl-xL inhibitors for treatment of highly metastatic GC. The gene discussed is BCL2L1; the disease is gastric cancer.